Completed PHASE2 INTERVENTIONAL 1-arm NCT00423930

Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

A Phase II Study of Radiotherapy (IMRT) + Cisplatin + Bevacizumab for Patients With Stage III/IV Head and Neck Cancers

Sponsor: Genentech, Inc.

Interventions bevacizumab cisplatin conventional surgery intensity-modulated radiation therapy

Updated 7 times since 2017 Last updated: Jul 19, 2017 Started: Oct 31, 2006 Primary completion: Jul 31, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Head and Neck Cancer and is currently completed. Genentech, Inc. leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States